Blanket Purchase Agreement 36F79724D0101-36E79726A0010
Award Date 1/16/26
Last Date to Order 1/15/27
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed Similar IDVs
- Bristol-Myers Squibb Company, headquartered in Lawrenceville, New Jersey, holds a multiple-award Federal Supply Schedule contract (36F79724D0101) for Pharmaceuticals and Drugs (FSS-61-IB) with a ceiling value of $12.28 billion, effective May 1, 2024 through April 30, 2029. This contract serves the Department of Veterans Affairs, including multiple Veterans Integrated Service Networks, and encompasses a comprehensive range of drugs, pharmaceuticals, and hematology-related products spanning...
- Bristol-Myers Squibb Company was awarded an indefinite-delivery/indefinite-quantity contract under the Pharmaceuticals and Drugs Federal Supply Schedule master contract by the Department of Veterans Affairs Veterans Health Administration. The contract provides for the delivery of specialized oncology pharmaceuticals to various Veterans Integrated Service Networks. Delivery orders issued against the contract to date have procured Bristol-Myers Squibb's BREYANZI and ABECMA treatments. BREYANZI...
- The U.S. Department of Veterans Affairs (VA) awarded a $10 million Blanket Purchase Agreement (BPA) to Servier Pharmaceuticals LLC, a for-profit pharmaceutical company, to provide the specialty oncology medications asparlas and oncaspar over a five-year period. This single-award BPA was issued against Servier's existing Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs. The VA has placed several fixed-price call orders against this BPA for delivery of asparlas and oncaspar...
- This Blanket Purchase Agreement, awarded on September 20, 2024, to Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.), provides the U.S. Department of Veterans Affairs with a $15 million indefinite delivery vehicle for the procurement of two critical oncology medications: BALVERSA (erdafitinib) and CARVYKTI. The single-award BPA is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carries an ultimate completion date of September 19, 2026. The...
- The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady...
- The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
- Novartis Pharmaceuticals Corporation has been awarded a single-award Blanket Purchase Agreement (BPA) by the National Acquisition Center with a ceiling value of $61.1 million and a performance period extending through October 1, 2026. This BPA, which carries no small business set-aside designation, is established against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and authorizes the procurement of four specialized pharmaceutical products: KYMRIAH, FABHALTA, NETSPOT, and...
- Servier Pharmaceuticals LLC was awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs National Acquisition Center on October 18, 2025, with a ceiling value of $16.8 million and a completion date of October 17, 2026. This BPA establishes a streamlined procurement vehicle for the supply of asparlas and Oncaspar (pegaspargase), specialty oncology chemotherapy agents used in cancer treatment programs serving the veteran population. The agreement operates under the...
- This federal contract Indefinite Delivery Vehicle (IDV) is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Incyte Corporation, a global biopharmaceutical company. The BPA, valued at $3,750,000, is for the supply of Pemazyre (pemigatinib), Incyte's specialized oncology drug used to treat certain types of cancer. The BPA, which runs through November 20, 2025, is issued under Incyte's Federal Supply Schedule (FSS-61-IB) contract...
- This Blanket Purchase Agreement (BPA) was awarded on December 3, 2025, by the Veterans Affairs National Acquisition Center to Incyte Corporation (UEI: ZTM9U2G5VTK8) for the supply of Pemazyre (pemigatinib), an oncology pharmaceutical product. The contract carries a ceiling value of $7.87 million and extends through December 2, 2026, with no small business set-asides applied. As a single-award BPA established under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), this contract...